GERN

Geron Corporation is a clinical biopharmaceutical company based in Foster City, California, specializing in the development and commercialization of innovative therapies for myeloid hematologic neoplasms. The company’s leading programs, including acalabrutinib and its proprietary telomerase inhibitor, are positioned to meet significant unmet medical needs in the field of blood cancers. With a robust pipeline and a strong emphasis on pioneering hematology research, Geron is committed to enhancing treatment outcomes and delivering transformative therapies that have the potential to significantly impact patient lives.